Infos Santé of Monday, 20 October 2014

Source: cameroon-tribune.cm

CIRCB prioritises HIV prevention/management in 2015

The third ordinary session of the Scientific Council ended on October 15, 2014 in Yaounde.

2015 research priorities at the “Chantal Biya” International Reference Centre for Research on Prevention and Management of HIV/AIDS (CIRCB) will focus on prevention and management of people living with HIV, particularly the mother-to-child transmission of HIV and the intensification of research on HIV patient’s resistance to the anti-retroviral drugs.

This was the major recommendation taken last Wednesday October 15, 2014 in the conference room of the research centre in Yaounde during the third ordinary meeting of the International Scientific Council chaired by Professor Carlo Federico Perno, chairman of the advisory body of CIRCB.

The director of the centre, Professor Alexis Ndjolo said the meeting was taking place 10 months after the last session held at the beginning of the year.

While noting that focus was on the mid-term scientific assessment of work done since the start of the year, Prof. Alexis Ndjolo said it was an occasion for members of the scientific committee to discuss with researchers in small groups in a bid to know what they were doing and what could be improved.

During discussions, the heads of the different research units took 15 minutes each to present their research works to the Scientific Council. Professor Carlo Federico Perno said the research centre will not only focus on the mother-to-child transmission of HIV, but will intensify research on the resistance to anti-retroviral drugs by some patients which is a serious and growing problem in the society today.

Besides studies on HIV vaccine and the social vaccine campaign which is taking place in various schools in the country, information indicates that work is underway to begin the clinical trial of the vaccine on HIV. Prof. Ndjolo noted that samples are available at CIRCB laboratory.

At the moment, the centre is putting in place all that is necessary to begin clinical trial on human beings in the nearest future.